Growth factor network disruption in prostate cancer progression

Cancer and Metastasis Reviews

Volumn 17, Issue 4, 1998, Pages 443-447

  Ware, Joy L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Growth factors; Networks; Prostate

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; CANCER GROWTH; EPITHELIUM CELL; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW;

EID: 0032773212     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006114527274     Document Type: Review

References (39)

1. Maygarden SJ, Novotny DB, Moul JL, Bae VL, Ware JL: Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. Mod Pathol 7: 930-936, 1994
2. Scher HI, Sarbis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Funks Z, Mendelson J, Cordon-Cardo C: Changing pattern of expression of the epidemal growth factor receptor and transforming growth alpha in the progression prostatic of neoplasms. Clin Cancer Res 1: 545-550, 1995
3. Freeman MR, Paul S, Haefer M, Ishibawa M, Adam RM, Renshaw AA, Elenius K, Klagsbrun M: Heparin-binding EGF-like growth factor in the human prostate: Synthesis predominately by intestinal and vascular smooth muscle cellsand action as a carcinoma cell mitogen. J Cell Biochem 68:328-338, 1998
4. Cohen P, Peehl DM, Lamson G, Rosenfield RG: Insulin-like growth factors (IGF), IGF receptors and IGF binding proteins in primary cultures of prostate epithelial cells. Clin Endoc Metab 73: 401-407, 1991
5. Longo A, Gianni S, Natali A, Costanini A, Vannello GB, Serio M: Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: characterization, tissue localization, and their modulators by chronic treatment gonadotrophin-releasing analog. J Clin Endocrinol Metab 72: 240-246, 1991
6. Tennant M, Thrasher J, Twomey P, Drivdahl R, Bimbaum R, Plymate S: Protein and messenger ribonucleic (mRNA)for the type I insulin-like growth factor (IGF) receptor isdecreased and IGF II mRNA is increased in human prostatecarcinoma compared to benign prostate epithelium. J Clin Endocrin Metab 81: 3774-3782, 1996
7. Tennant M, Thrasher JB, Twomey PA, Bimbaum R, Plymate S: Insulin-like growth factor binding proteins (IGFBP) -4, -5, -6 in the benign and malignant human prostate: IGFBPS messenger ribonucleic acid localization differs from IGFBP -5 protein localization. J Clin Endocrinol Metab 81: 3783-3792, 1996
8. Boudon C, Rodier G, Lechevallier E, Mottet N, Barenton N, Sultan C: Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostaticcells in culture. J Clin Endocrinol Metab 81: 612-617, 1996
9. Plymate S, Hwa V, Thomasini C, Maddison L, Thrasher JB, Swisshelm K, Rosenfeld RG: Insulin-like growth factor binding protein 7 expression and regulation in the human prostate. Prog Endocrine Soc 1997, p 351 (abstract)
10. Ware JL, Strom SC, Maygarden SJ: Immunohistochemical evidence for expression of the c-erb B-2 protein in human prostatic carcinoma. Hum Pathol 22: 254-258, 1991
11. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW: Expression of the c-erb B2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 150: 1427-1433, 1993
12. Yan G, Fukabori Y, Nikolaropuolos S, Wang F, McKeehan WL: Heparin-binding keritinocyte growth factor is a candidate stromal-to-epithelial andromedin. Mol Endocrinol 6:2123-8, 1992
13. Ropiquet F, Berthon P, Villette JM, LeBrun G, Maitland NJ, Cussenot O, Fiet J: Constitutive expression of FGF2/bFGFin non-tumorgenetic human prostatic epithelial cells resultsin the acquisition of a partial neoplastic phenotype. Int J Cancer 72: 543-7, 1997
14. Kim IY, Ahn HJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazara K, Nemeth JA, Kozlowski JM, Lee C: Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 2: 1255-1261, 1996
15. Guo Y, Kyprianov N: Overexpression of transforming growth factor (TGF) beta type II receptor restores TGF beta sensitivity and signaling in human prostate cancer cells. Cell Growth Differ 9: 185-93, 1998
16. Peusner L: Studies in Network Thermodynamics. Elsevier Publishing, Amsterdam, 1986
17. Mikalecky DC: A comparison between the formal description of reaction and neural networks: A network thermodynamic approach. In: Mikalecky DC, Clarke AM (ed) Biomedical Engineering: Opening New Doors, New York University Press. New York, 1990, pp 67-74
18. Hopfield JJ, Tanks DW: Computing with neural circuits: amodel. Science 233: 625-633, 1986
19. Elson SD, Browne CA, Thorburn GG: Identification of epidermal growth factor-like activity in human male reproductive tissue and fluids. J Clin Endocrinol Metab 48: 673-679, 1984
20. Moul JW, Maygarden SJ, Ware JL, Mohler JL, Maher PD, Schenkman NS, Ho CK: Cathepsin D and epidermal growth factor receptors (EGFR) immunohistochemistry does not predict outcome of prostate cancer patients undergoing radical prostatetectomy. J Urol 155: 982-985, 1996
21. Robinson D, Feng H, Pretlow T, Kung HJ: A tyrosine kinase profile of a prostate carcinoma. Proc Nat Acad Sci USA 93: 5958-5962, 1996
22. Fong CJ, Sherwood ER, Mendleson J, Lee C, Kozlowski JM: Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitized androgen-independent prostatic carcinoma cells to tumor neurosis factor α. Cancer Res 52: 5887-5892, 1992
23. Ching KZ, Ramsay CE, Pethgrew N, Cunha RH, Jason M, Dodd JG: Expression of mRNA for epidermal growth factor, transforming growth factor alpha, and their receptor in human prostate tissue and cell lines. Mol Cell Biochem 126:151-158, 1993
24. Bae VL, Jackson-Cook CK, Brothman AR, Maygarden SJ, Ware JL: Tumorigeniaty of SV40T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. Int J Cancer 58: 721-729, 1994
25. Angellon-Nicoud P, Benoux M: Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IFG-binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinol 136: 5485-5492, 1995
26. Pietizkowski Z, Mulholland G, Gomella L, Jameson B,Wermicle D, Baserga R: Inhibition of growth of prostaticcancer cell lines by peptide analogues of insulin-like growthfactor I. Cancer Res 53: 1102-1106, 1993
27. Jackson-Cook C, Bae V, Edelman W, Brothman A, Ware J: Cytogenetic characterization of the human prostate cancer cell line P69SV40T and its novel tumorgenic sublines M2182 and M15. Cancer Genet Cytogenet 87: 14-23, 1996
28. Bae VL, Jackson-Cook CK, Maygarden SJ, Plymate S, Chen J, Ware JL: Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 34: 275-282, 1998
29. Watson BW, Ware JL, Ferreira-Gonzalez A, Wilkinson DS, Garrett CT: Identification of subchromosumal regions associated with phenotypic changes in a human prostate cancer model using microsatellite loss of heterozygosity (LOH)analysis. Proc Am Assoc Cancer Res 39: 342 (Abstract 2339), 1998
30. Plymate SR, Bae VL, Maddison L, Quinn LS, Ware JL:Re-expression of the type 1 IGF receptor (IGF-IR) inhibitsthe malignant phenotype of SV40 T-immortalized human prostate epithelial cells. Endocrinol 138: 1728-1735, 1997
31. Damon SE, Maddison L, Ware JL and Plymate SR: Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostatic tumor formation. Endocrinol 139: 3456-3464, 1998
32. Webber MM, Bello D, Quader S: Immortalized and tumorgenic adult human prostatic epithelial cell lines: characteristics and applications. Part 2. Tumorgenic cell lines. Prostate 30: 58-64, 1997
33. Niederberger C: Computational tools for the modern andrologist. J Androl 17: 462-466, 1996
34. Prideaux JA, Mikulecky DC, Clarke AM, Ware JL: A modified neural network model of tumor cell interactions and sub-population dynamics. Invasion Metastasis 13: 50-56, 1993
35. Miles BJ, Katlan MW: Computer modeling of prostate cancer treatment. A paradigm for oncologic management. Surg Oncol Clin N Am 4: 361-372, 1995
36. Tewan A, Narayan P: Novel staging for localized prostate cancer: a pilot study using genetic adaptive neural networks. J Urol 160: 430-436, 1998
37. Douglas TH, Moul JW: Applications of neural networks inurologic oncology. Semin Urol Oncol 16: 35-39, 1998
38. Vawer A, Rashbass J: The biological toolbox: a computer program for simulating basic biological and pathological processes. Comput Meth Programs Biomed 52: 203-211, 1997
39. Haas GP, Sakr W: Epidemiology of prostate cancer. CA 47:273-287, 1997